Companies Dominating the Esketamine Nasal Spray Market
- Eli Lilly & Company
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bristol Myers Squibb Company
- Novartis International AG
- Bausch Health Companies Inc.
- Validus Pharmaceuticals LLC
- Pfizer Inc.
- AbbVie Inc.
- Merck KGaA
- Endo International Plc
- MedKoo Biosciences, Inc.
Browse Key Market Insights with Data Illustration:
In the News
- The Massachusetts General Brigham (MGB) led a new study that matched subanesthetic intravenous ketamine to electroconvulsive treatment (ECT) for the therapy of non-psychotic, treatment-resistant depression. The outcomes are released in the New England Journal of Medicine. In a clinical trial of 403 patients investigators discovered that 55 percent of those who got ketamine therapy suffered a constant betterment in depressive symptoms without major adverse impacts.
- Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Mindset Pharma, Inc. (Mindset) confirmed that they have come into a conclusive planning agreement according to which Otsuka will obtain Mindset for approximately CAD 80 million in an all-cash deal. This agreement has been performed through Otsuka America, Inc. (OAI), a wholly-owned subsidiary of Otsuka. The Otsuka and Mindset boards of directors have accepted the deal. The purchase is anticipated to be completed during the fourth quarter of 2023, subject to needed techniques.
